Get Premium to unlock powerful stock data
FRA:49BA (Cayman Islands)  
BeiGene Ltd logo

BeiGene Ltd

€ 154.00 (-3.14%) Jun 29
P/E:
At Loss
P/B:
3.58
Market Cap:
€ 15.91B ($ 16.63B)
Enterprise V:
€ 11.00B ($ 11.50B)
Volume:
20.00
Avg Vol (2M):
26.00
Also Trade In:
Volume:
20.00
Market Cap €:
15.91B
Market Cap $:
16.63B
PE Ratio:
At Loss
Avg Vol (2-Month):
26.00
Enterprise Value €:
11.00B
Enterprise Value $:
11.50B
PB Ratio:
3.58
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website Sources Stock Report
Dataset
Financial Download Tutorials

Business Description

BeiGene Ltd
NAICS : 325412 SIC : 2834
c/o Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman, CYM, KY1-1108
Description
BeiGene Ltd is a commercial-stage biotechnology company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1. Its geographical segments are China, the United States, and the Rest of the world.
Name Current Vs Industry Vs History
Cash-To-Debt 9.3
Equity-to-Asset 0.73
Debt-to-Equity 0.11
Debt-to-EBITDA -0.35
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 4.3
Distress
Grey
Safe
Beneish M-Score -1.83
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 56.89
9-Day RSI 59.16
14-Day RSI 57.31
6-1 Month Momentum % -45.61
12-1 Month Momentum % -57.53

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 5.05
Quick Ratio 4.87
Cash Ratio 4.54
Days Inventory 35.11
Days Sales Outstanding 80.04
Days Payable 43.3

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -19.9

Financials (Next Earnings Date:2022-08-05 Est.)

FRA:49BA's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

EMBED

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil €) 767.755
EPS (TTM) (€) -17.41
Beta 0.27
Volatility % 39.81
14-Day RSI 57.31
14-Day ATR (€) 6.902898
20-Day SMA (€) 139.75
12-1 Month Momentum % -57.53
52-Week Range (€) 113 - 370
Shares Outstanding (Mil) 103.28

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

BeiGene Ltd Filings

Document Form Filing Date
No Filing Data